Syndax Pharmaceuticals Inc (SNDX NASDAQ) stock market data APIs
$19.4383
0.04(0.2%)
as of May 19, 2026
Try our APIs with
free plan!
Syndax Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Prev. Close
19.4383
Open
19.477
High
19.477
Low
18.8764
52 wk Range
8.585-25.59
Market Cap
1 703 M
Shares Outstanding
88 610 K
Revenue
217 M
EPS
-0.48
Beta
0.414
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Syndax Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Syndax Pharmaceuticals Inc data using free add-ons & libraries
Get Syndax Pharmaceuticals Inc Fundamental Data
Syndax Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 217 M
- EBITDA: -223 768 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Syndax Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-11
- EPS/Forecast: -0.5975
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Syndax Pharmaceuticals Inc News
New
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the best small cap stocks to buy for 10x potential. On May 4, Stifel lifted the price target on Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to $46 f...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2...
Syndax outlines 2026 operating expense target of approximately $400M as Revuforj expands in NPM1
Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q1 2026 MANAGEMENT VIEW * “In the first quarter, we delivered over $100 million in combined sales of Revuforj and Niktimvo, underscoring rob...
Syndax Pharmaceuticals Q1 Earnings Call Highlights
Syndax Pharmaceuticals logo Key Points Over $100 million in combined Q1 net sales — Revuforj $49M and Niktimvo $55M — with both products annualizing near $200M and Revuforj growth driven by NCCN...
Get Syndax Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
